@article{KosterGurumurthyKumaretal.2022,
  author    = {Koster, Stefanie and Gurumurthy, Rajendra Kumar and Kumar, Naveen and Prakash, Pon Ganish and Dhanraj, Jayabhuvaneshwari and Bayer, Sofia and Berger, Hilmar and Kurian, Shilpa Mary and Drabkina, Marina and Mollenkopf, Hans-Joachim and Goosmann, Christian and Brinkmann, Volker and Nagel, Zachary and Mangler, Mandy and Meyer, Thomas F. and Chumduri, Cindrilla},
  title     = {Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming},
  series = {Nature Communications},
  volume    = {13},
  journal   = {Nature Communications},
  number    = {1},
  doi       = {10.1038/s41467-022-28569-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-301349},
  year      = {2022},
  abstract  = {Coinfections with pathogenic microbes continually confront cervical mucosa, yet their implications in pathogenesis remain unclear. Lack of in-vitro models recapitulating cervical epithelium has been a bottleneck to study coinfections. Using patient-derived ectocervical organoids, we systematically modeled individual and coinfection dynamics of Human papillomavirus (HPV)16 E6E7 and Chlamydia, associated with carcinogenesis. The ectocervical stem cells were genetically manipulated to introduce E6E7 oncogenes to mimic HPV16 integration. Organoids from these stem cells develop the characteristics of precancerous lesions while retaining the self-renewal capacity and organize into mature stratified epithelium similar to healthy organoids. HPV16 E6E7 interferes with Chlamydia development and induces persistence. Unique transcriptional and post-translational responses induced by Chlamydia and HPV lead to distinct reprogramming of host cell processes. Strikingly, Chlamydia impedes HPV-induced mechanisms that maintain cellular and genome integrity, including mismatch repair in the stem cells. Together, our study employing organoids demonstrates the hazard of multiple infections and the unique cellular microenvironment they create, potentially contributing to neoplastic progression.},
  language  = {en}
}
@article{NadellaMohantySharmaetal.2018,
  author    = {Nadella, Vinod and Mohanty, Aparna and Sharma, Lalita and Yellaboina, Sailu and Mollenkopf, Hans-Joachim and Mazumdar, Varadendra Balaji and Palaparthi, Ramesh and Mylavarapu, Madhavi B. and Maurya, Radheshyam and Kurukuti, Sreenivasulu and Rudel, Thomas and Prakash, Hridayesh},
  title     = {Inhibitors of Apoptosis Protein Antagonists (Smac Mimetic Compounds) Control Polarization of Macrophages during Microbial Challenge and Sterile Inflammatory Responses},
  series = {Frontiers in Immunology},
  volume    = {8},
  journal   = {Frontiers in Immunology},
  number    = {1792},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2017.01792},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197484},
  year      = {2018},
  abstract  = {Apoptosis is a physiological cell death process essential for development, tissue homeostasis, and for immune defense of multicellular animals. Inhibitors of apoptosis proteins (IAPs) regulate apoptosis in response to various cellular assaults. Using both genetic and pharmacological approaches we demonstrate here that the IAPs not only support opportunistic survival of intracellular human pathogens like Chlamydia pneumoniae but also control plasticity of iNOS+ M1 macrophage during the course of infection and render them refractory for immune stimulation. Treatment of Th1 primed macrophages with birinapant (IAP-specific antagonist) inhibited NO generation and relevant proteins involved in innate immune signaling. Accordingly, birinapant promoted hypoxia, angiogenesis, and tumor-induced M2 polarization of iNOS+ M1 macrophages. Interestingly, birinapant-driven changes in immune signaling were accompanied with changes in the expression of various proteins involved in the metabolism, and thus revealing the new role of IAPs in immune metabolic reprogramming in committed macrophages. Taken together, our study reveals the significance of IAP targeting approaches (Smac mimetic compounds) for the management of infectious and inflammatory diseases relying on macrophage plasticity.},
  language  = {en}
}